Filing Analysis
Elite Health Systems Inc. entered into a $525,000 subordinated note and warrant agreement with its CEO and Chair, Dr. Prasad Jeereddi, on July 31, 2026. The deal includes an option for the company to take up to an additional $1.5 million from the same insider.
🚩 Red Flags
- Related-party transaction: The financing is provided by the CEO/Chair, creating a potential conflict of interest regarding terms and dilution.
- High-interest debt: 10% per annum on unsecured subordinated debt to an insider.
- Potential for significant dilution via warrants (110,526 shares) that are not currently registered.
- Short maturity: The note is due in only one year (July 31, 2027).
📋 Key Facts
- The Company entered into a $525,000 unsecured subordinated note with CEO/Chair Dr. Prasad Jeereddi on July 31, 2026.
- The note carries a 10% annual interest rate and is due on July 31, 2027.
- A 2% prepayment penalty applies to the note.
- A warrant agreement was signed allowing Dr. Jeereddi to purchase up to 110,526 shares at $0.95 per share through July 31, 2031.
- The company has the option to accept up to an additional $1.5 million in investment from the CEO under similar terms.
Elite Health Systems Inc. has authorized management to explore strategic alternatives, including potential asset sales, mergers, or capital raises. The company explicitly warns that failure to secure a transaction could materially impact its liquidity and ability to continue operations.
🚩 Red Flags
- Implicit liquidity risk: The filing states failure to find a deal could have a 'material adverse effect' on the ability to continue operations.
- Capital intensive growth model: Management admits that growing membership requires significant capital and time, which they currently lack.
- Strategic review often precedes bankruptcy or distressed sale in micro-cap contexts.
📋 Key Facts
- Board of Directors authorized a review of strategic alternatives on July 10, 2026.
- Potential actions include equity/debt financing, selling operating businesses, or a merger/disposition of all assets.
- The company notes it must significantly increase healthcare membership to remain successful, requiring significant capital and time.
- No timetable has been established for any potential transaction.
Elite Health Systems Inc. held a Special Meeting on September 26, 2025, where stockholders approved several key items including the election of five directors and an equity incentive plan. Notably, shareholders approved the acquisition of Physician Support Systems, Inc. (PSS) via a share exchange involving 3,158,000 shares.
🚩 Red Flags
- Significant dilution potential due to the approval of a new Equity Incentive Plan (4.5M shares) and the PSS acquisition (3.16M shares).
- The increase in authorized shares from 25M to 50M provides significant headroom for future dilutive equity offerings.
📋 Key Facts
- Special Meeting held on September 26, 2025.
- Quorum present: 14,688,791 votes cast out of 21,939,924 eligible shares.
- Approved the election of five directors (Jeereddi, Gold, Leimkuhler, St. Lawrence, Policherla).
- Approved amendment to Certificate of Incorporation to increase authorized common stock from 25M to 50M shares.
- Approved 2025 Equity Incentive Plan with a maximum of 4,500,000 shares.
- Approved acquisition of Physician Support Systems, Inc. (PSS) via issuance of 3,158,000 common shares.
- Ratified Mercurius & Associates LLP as independent auditors for FY2025.
Elite Health Systems Inc. entered into a Share Exchange Agreement to acquire 100% of Physician Support Systems, Inc. (PSS) in exchange for 3,158,000 shares of common stock. The transaction involves significant related-party interests as the CEO and his daughter are the primary sellers.
🚩 Red Flags
- Significant related-party transaction: The CEO and his immediate family are the direct beneficiaries of the share issuance.
- Potential dilution: Issuance of 3,158,000 new common shares requires an amendment to increase authorized stock.
📋 Key Facts
- Date of agreement: September 26, 2025
- Acquisition target: 100% of Physician Support Systems, Inc. (PSS)
- Consideration: 3,158,000 shares of Elite Health Systems Inc. common stock
- Related Party Detail: CEO Dr. Prasad Jeereddi owns 46% of PSS; his daughter, Dr. Praveena Jeereddi, owns 44% of PSS
- Transaction is subject to stockholder approval and an amendment to the Certificate of Incorporation to increase authorized shares
Elite Health Systems Inc.'s subsidiary, Elite Health Plan, Inc., has executed a contract with the Centers for Medicare and Medicaid Services (CMS) to operate as an MA/MA-PD organization. The company expects to begin onboarding members in October 2025.
🚩 Red Flags
- Revenue and enrollment are subject to annual renewal risks from CMS.
📋 Key Facts
- Elite Health Plan, Inc. (wholly owned subsidiary) signed a CMS Contract on August 28, 2025.
- The contract establishes Elite Health Plan as a federally qualified HMO contracted with CMS.
- Onboarding of members is expected to commence in October 2025.
- Enrollment is contingent upon the annual renewal of the CMS Contract.
Elite Health Systems Inc. announced two key leadership changes effective July 26, 2025: the appointment of Dr. Haranath Policherla to the Board and Ken Minor as Chief Financial Officer.
🚩 Red Flags
- The appointment of a fractional CFO (via Spotlight CFO Services) may indicate the company is not yet ready for a full-time, permanent finance executive, common in micro-cap companies seeking to manage burn rates.
📋 Key Facts
- Dr. Haranath Policherla appointed as a non-executive director on July 26, 2025; he is a neurologist with extensive healthcare leadership experience.
- Ken Minor appointed as Chief Financial Officer (CFO) on July 26, 2025.
- Ken Minor previously served as the Company's financial advisor and Secretary since April 2024 via his firm, Spotlight CFO Services.
Elite Health Systems Inc. has commenced a private placement of common stock seeking up to $5 million in gross proceeds at $0.95 per share. The filing also reveals a non-binding letter of intent to acquire Physician Support Systems, Inc. (PSS) via a stock-for-stock transaction involving the CEO's family members.
🚩 Red Flags
- Related-party transaction: The acquisition target (PSS) is owned by the CEO and his daughter.
- Significant dilution risk: Proposed increase in authorized shares to 50,000,000 shares suggests massive potential dilution for existing shareholders.
- Highly speculative business model: Subsidiary 'Elite Health' has a limited operating history and is awaiting final CMS approval/bids for Medicare Advantage contracts.
📋 Key Facts
- Commenced private placement of common stock on July 2, 2025.
- Expected gross proceeds: minimum $2,000,000 to maximum $5,000,000.
- Offering price: $0.95 per share.
- Company intends to increase authorized shares from current levels to 50,000,000 via shareholder vote.
- Entered into a non-binding LOI to acquire 100% of Physician Support Systems, Inc. (PSS) for 3,158,000 shares of common stock.
- The CEO, Dr. Prasad Jeereddi, owns 51% of the target company (PSS).
- Proceeds are intended for development of Elite Health Plan, Inc. and integration of PSS.
Elite Health Systems Inc. announced a ticker symbol change from USNU to EHSI, effective June 10, 2025, following notification from FINRA.
📋 Key Facts
- Ticker symbol changing from USNU to EHSI.
- Change effective date: June 10, 2025.
- Trading will occur on the OTC market at market open.
- FINRA notified the company that all necessary information has been processed.
Elite Health Systems Inc. announced that its subsidiary, Elite Health Plan, Inc., received conditional approval from CMS for its 2026 Medicare Advantage/Medicare – Prescription Drug (MA-Only/MA-PD) application. Final approval is contingent upon bid acceptance and successful pre-implementation testing.
🚩 Red Flags
- Regulatory uncertainty: The filing explicitly states there is no assurance that CMS will ultimately approve the bid or that the entity can maintain its license/approval.
📋 Key Facts
- Conditional approval received from CMS on June 3, 2025, for the CY 2026 Medicare Advantage/Medicare – Prescription Drug (MA-Only/MA-PD) application.
- The subsidiary filed its CY 2026 PBP HMO bid submission on June 2, 2025, in partnership with Wakely Consulting Group.
- Final approval depends on CMS approving the specific bid and formulary under 42 CFR 422 Subpart D and 42 CFR 423 Subpart F.
- The company must also complete all pre-implementation activities, including system and data testing.
Elite Health Systems Inc.'s subsidiary, Elite Health Plan, Inc., has been awarded a full-service health care service plan license in California under the Knox-Keene Act. The company is now preparing for its 2026 CMS bid submission, subject to federal regulatory approvals.
🚩 Red Flags
- Significant regulatory dependency: The business model relies heavily on upcoming CMS bid approvals which are not guaranteed.
- Complexity risk: Management explicitly notes the 'complex' nature of the regulatory process and the lack of assurance regarding CMS approval or license maintenance.
📋 Key Facts
- Subsidiary 'Elite Health Plan, Inc.' awarded a full-service health care service plan license via the Knox-Keene Health Care Service Plan Act of 1976.
- License allows operations within the state of California subject to CMS approvals and regulatory compliance.
- The company expects to file its calendar year 2026 bid submission to CMS in the coming days.
- Operational status is contingent upon successful CMS approval of bids and ongoing maintenance of license requirements.
Elite Health Systems Inc. has amended the terms of its existing private placement to increase the maximum aggregate capital raise from $5.05 million to $5.5 million. Additionally, the Board approved the issuance of 480,000 common shares to directors and officers as non-cash compensation.
🚩 Red Flags
- Issuance of equity (480,000 shares) to insiders in lieu of cash compensation suggests potential liquidity constraints or a desire to preserve cash.
- Continued reliance on private placements for capital raising is typical for micro-cap companies but indicates ongoing need for external funding.
📋 Key Facts
- Amended private placement terms allow for a maximum aggregate raise of up to $5,500,000 (previously ~$5.05 million).
- The company has raised approximately $5.05 million via private placement since January 16, 2024.
- Board approved issuance of 480,000 shares of Common Stock to directors and officers in lieu of cash compensation for services through fiscal year 2024.
- Effective date of Board actions: November 29, 2024.
Elite Health Systems, Inc. (formerly U.S. Neurosurgical Holdings, Inc.) has officially changed its legal name effective September 30, 2024. The company is also in the process of updating its ticker symbol and corporate website.
📋 Key Facts
- Legal name changed from U.S. Neurosurgical Holdings, Inc. to Elite Health Systems, Inc., effective Sept 30, 2024.
- The Board approved the Charter Amendment pursuant to Section 242 of Delaware General Corporation Law.
- Applied to FINRA on Sept 25, 2024, to change ticker symbol to either 'EHSI' or 'ELIT'.
- Approval for new ticker is expected within two to four weeks.
U.S. NeuroSurgical Holdings, Inc. announced a significant leadership overhaul effective July 10, 2024, including the resignation of its President and Chairman, Alan Gold, and Director Charles Merriman. Dr. Prasad A. Jeereddi has been appointed as the new CEO and Chairman.
🚩 Red Flags
- Simultaneous departure of the President/Chairman and a Director (multiple officer departures).
- Appointment of an insider (beneficial owner of 1.5M shares) to the CEO and Chairman roles.
- Need for increased capital raising (amending private placement up to $5M) suggests ongoing liquidity needs.
📋 Key Facts
- Effective July 10, 2024, Mr. Alan Gold resigned as President but remains on the Board; he also stepped down as Chairman.
- Mr. Charles H. Merriman resigned from the Board and all committees effective July 10, 2024.
- Dr. Prasad A. Jeereddi appointed as CEO and Chairman of the Board, effective immediately.
- The Company amended its private placement terms to increase the maximum capital raise from $2.8 million (already raised) to up to $5,000,000.
- Dr. Jeereddi is a beneficial owner of approximately 1.5 million shares of Common Stock.
U.S. NeuroSurgical Holdings, Inc. announced the initial closing of a private placement of common stock, raising $1,000,000 at $0.50 per share. The company intends to use the proceeds primarily to fund its subsidiary, Elite Health Plans, Inc., which operates as a Medicare Advantage plan.
🚩 Red Flags
- Low share price ($0.50) often associated with micro-cap volatility or potential future reverse splits to maintain listing requirements.
- The subsidiary (Elite Health) has a 'limited operating history' and is the primary focus of capital expenditure.
📋 Key Facts
- Initial closing raised $1,000,000 in gross proceeds.
- Private placement price is $0.50 per share.
- The company expects a second closing to raise up to an additional $1,000,000.
- Proceeds are earmarked for developing Elite Health Plans, Inc. (a wholly-owned subsidiary) and administrative activities.
- Elite Health plans to operate as a Medicare Advantage plan in Nevada and California.